Explore how tau-targeting drug Diranersen and a newly diversified research pipeline are reshaping Alzheimer's treatment and slowing cognitive decline.

If your clinical trial recruitment strategy still relies on cold-calling lists of "eligible" patients scraped from five-year-old EHR data, you aren’t just behind the times—you’re actively sabotaging your own FDA compliance.